Trafficking of adeno‐associated virus vectors across a model of the blood–brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Neurochemistry

• Publication date

  2017-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/jnc.13861PMID 27718541PMCID PMC5298820
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene

  2015cited by this paper
• AAV9 supports wide-scale transduction of the CNS and TDP-43 disease modeling in adult rats

  2015cited by this paper
• Moving towards treatments for spinal muscular atrophy: hopes and limits

  2015cited by this paper
• Gene Therapy for the Nervous System: Challenges and New Strategies

  2014cited by this paper
• Recombinant Adeno-Associated Virus Utilizes Host Cell Nuclear Import Machinery To Enter the Nucleus

  2014cited by this paper
• Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10.

  2014cited by this paper
• Chondroitin Sulfate is the Primary Receptor for a Peptide-Modified AAV That Targets Brain Vascular Endothelium In Vivo

  2014cited by this paper
• Translational Fidelity of Intrathecal Delivery of Self-Complementary AAV9–Survival Motor Neuron 1 for Spinal Muscular Atrophy

  2014cited by this paper
• Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo.

  2014cited by this paper
• Transendothelial migration of effector T cells across inflamed endothelial barriers does not require heparan sulfate proteoglycans.

  2014influential reference
• Viral vectors: a look back and ahead on gene transfer technology.

  2013cited by this paper
• Mouse gender influences brain transduction by intravascularly administered AAV9.

  2013cited by this paper
• Microvesicle-associated AAV vector as a novel gene delivery system.

  2012cited by this paper
• Identification of the Galactose Binding Domain of the Adeno-Associated Virus Serotype 9 Capsid

  2012cited by this paper
• Quantitative 3D tracing of gene-delivery viral vectors in human cells and animal tissues.

  2012cited by this paper
• Cytoplasmic Trafficking, Endosomal Escape, and Perinuclear Accumulation of Adeno-Associated Virus Type 2 Particles Are Facilitated by Microtubule Network

  2012cited by this paper
• Adeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman Primates

  2012cited by this paper
• Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors

  2011cited by this paper
• Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates.

  2011cited by this paper
• The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice.

  2011cited by this paper
• Gender dimorphism in the gut: mucosal protection by estrogen stimulation of IgA transcytosis.

  2011cited by this paper
• Systemic Gene Delivery in Large Species for Targeting Spinal Cord, Brain, and Peripheral Tissues for Pediatric Disorders

  2011cited by this paper
• Terminal N-Linked Galactose Is the Primary Receptor for Adeno-associated Virus 9*

  2011cited by this paper
• Establishment of primary cultures of human brain microvascular endothelial cells to provide an in vitro cellular model of the blood-brain barrier

  2010cited by this paper
• Unique molecular signatures of disease brain endothelia provide a novel site for CNS-directed enzyme therapy

  2009cited by this paper
• Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons.

  2009cited by this paper
• Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes

  2009cited by this paper
• Activation of Peroxisome Proliferator-Activated Receptor γ (PPARγ) Suppresses Rho GTPases in Human Brain Microvascular Endothelial Cells and Inhibits Adhesion and Transendothelial Migration of HIV-1 Infected Monocytes1

  2008cited by this paper
• Balamuthia mandrillaris interactions with human brain microvascular endothelial cells in vitro.

  2007cited by this paper
• Blood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions

  2006cited by this paper
• Astrocyte–endothelial interactions at the blood–brain barrier

  2006cited by this paper
• Rho-mediated regulation of tight junctions during monocyte migration across the blood-brain barrier in HIV-1 encephalitis (HIVE).

  2006cited by this paper
• AAV transcytosis through barrier epithelia and endothelium.

  2006cited by this paper
• Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain.

  2003cited by this paper
• Transport of Human Immunodeficiency Virus Type 1 Pseudoviruses across the Blood-Brain Barrier: Role of Envelope Proteins and Adsorptive Endocytosis

  2001cited by this paper
• Adeno-Associated Virus-Mediated Gene Transfer to the Brain: Duration and Modulation of Expression

  1999cited by this paper
• Adsorptive endocytosis mediates the passage of HIV-1 across the blood-brain barrier: evidence for a post-internalization coreceptor.

  1998cited by this paper
• Estrogen-stimulated transcytosis of desialylated ligands and alpha2 macroglobulin in rat liver.

  1997cited by this paper
• Adsorptive endocytosis and membrane recycling by cultured primary bovine brain microvessel endothelial cell monolayers.

  1990cited by this paper

• The delivery challenge of adeno-associated virus vector-based gene therapies for neurological diseases

  2026cites this paper
• Intravenous rAAV9 Produces Time-Resolved Parenchymal Labeling Downstream of the Vasculature in Adult Mice

  2026cites this paper
• Microphysiological systems to accelerate and De-risk AAV Gene therapy development.

  2026cites this paper
• Metadata assessment of non-human primate studies of AAV9 uncovers potential tissue specific variation in expression efficiency.

  2026cites this paper
• AAV9 Gene Therapy in Type II GM1 Gangliosidosis - A Phase 1-2 Trial.

  2026cites this paper
• Structural studies of Parvoviridae capsid assembly and evolution: implications for novel AAV vector design

  2025cites this paper
• Investigational Gene Therapies for Parkinson's Disease

  2025cites this paper
• Recent advances in blood-brain barrier-on-a-chip models.

  2025cites this paper
• AAV9 Gene Therapy in GM1 Gangliosidosis Type II: A Phase 1/2 Trial

  2025cites this paper
• Skeleton keys and Trojan horses: a review of therapeutic delivery to the brain

  2025cites this paper
• Overcoming the blood-brain barrier: targeted delivery strategies for gliomas

  2025cites this paper
• PET imaging of AAV9 and AAVBR1 trafficking in normal mice

  2025cites this paper
• Viral vectors in neurodegenerative diseases: immune responses and therapeutic applications

  2025cites this paper
• Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside

  2024cites this paper
• Recent Progress in Nanomedicine for the Diagnosis and Treatment of Alzheimer's Diseases.

  2024cites this paper
• Adeno-associated Virus-Mediated Gene Delivery Across the Blood-Brain Barrier.

  2024cites this paper
• Advancing Blood–Brain Barrier-on-a-Chip Models Through Numerical Simulations

  2024cites this paper
• Neurosurgical gene therapy for central nervous system diseases

  2024cites this paper
• The Glycocalyx: The Importance of Sugar Coating the Blood-Brain Barrier

  2024cites this paper
• Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications.

  2024cites this paper
• Identification of new AAV vectors with enhanced blood-brain barrier penetration efficiency via organ-on-a-chip.

  2024cites this paper
• An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery

  2024cites this paper
• P2Y1 receptor in Alzheimer’s disease

  2024cites this paper
• Rescue of myocytes and locomotion through AAV2/9-2YF intracisternal gene therapy in a rat model of creatine transporter deficiency

  2024cites this paper
• Natural Adeno-Associated Virus Serotypes and Engineered Adeno-Associated Virus Capsid Variants: Tropism Differences and Mechanistic Insights

  2024cites this paper
• NeuroD1 Regulated Endothelial Gene Expression to Modulate Transduction of AAV-PHP.eB and Recovery Progress after Ischemic Stroke

  2023cites this paper
• An AAV capsid reprogrammed to bind human Transferrin Receptor mediates brain-wide gene delivery

  2023cites this paper
• Prospective approaches to gene therapy computational modeling – spotlight on viral gene therapy

  2023cites this paper
• Whole-Body Disposition and Physiologically Based Pharmacokinetic Modeling of Adeno-Associated Viruses and the Transgene Product.

  2023cites this paper
• An Induced Pluripotent Stem Cell-Derived Human Blood–Brain Barrier (BBB) Model to Test the Crossing by Adeno-Associated Virus (AAV) Vectors and Antisense Oligonucleotides

  2023cites this paper
• Diagnosis and Treatment of Pantothenate Kinase-Associated Neurodegeneration (PKAN): A Systematic Review

  2023cites this paper
• Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 Gangliosidosis

  2023cites this paper
• Systemic gene therapy rescues retinal dysfunction and hearing loss in a model of Norrie disease

  2023cites this paper
• Understanding the role of endothelial cells in brain tumor formation and metastasis: a proposition to be explored for better therapy

  2023cites this paper
• Blood-Brain Barrier (BBB)-Crossing Strategies for Improved Treatment of CNS Disorders.

  2023cites this paper
• Therapeutic strategy for Fabry disease by intravenous administration of adeno‐associated virus 2 or 9 in α‐galactosidase A‐deficient mice

  2023influential citation
• Human in vitro blood barrier models: architectures and applications

  2023cites this paper
• Clinical gene therapy development for the central nervous system: Candidates and challenges for AAVs.

  2023cites this paper
• Structural and functional characterization of capsid binding by anti-AAV9 monoclonal antibodies from infants after SMA gene therapy.

  2023cites this paper
• A blood-brain barrier-penetrating AAV2 mutant created by a brain microvasculature endothelial cell-targeted AAV2 variant

  2023influential citation
• Incisionless targeted adeno-associated viral vector delivery to the brain by focused ultrasound-mediated intranasal administration

  2022cites this paper
• Microvasculopathy in spinal muscular atrophy is driven by a reversible autonomous endothelial cell defect

  2022cites this paper
• Emerging Perspectives on Gene Therapy Delivery for Neurodegenerative and Neuromuscular Disorders

  2022cites this paper
• Cell Reprogramming for Regeneration and Repair of the Nervous System

  2022cites this paper
• Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood–brain barrier in rodents and primates

  2022cites this paper
• Selection of rAAV vectors that cross the human blood-brain barrier and target the central nervous system using a transwell model

  2022influential citation
• Fantastic AAV Gene Therapy Vectors and How to Find Them—Random Diversification, Rational Design and Machine Learning

  2022cites this paper
• Blood–brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders

  2022cites this paper
• The multifaceted actions of the lncRNA H19 in cardiovascular biology and diseases

  2022cites this paper
• Assessment of AAV9 distribution and transduction in rats after administration through Intrastriatal, Intracisterna magna and Lumbar Intrathecal routes

  2022influential citation
• Microfluidic strategies for the blood-brain barrier construction and assessment

  2022cites this paper
• A novel strategy for delivering Niemann‐Pick type C2 proteins across the blood–brain barrier using the brain endothelial‐specific AAV‐BR1 virus

  2022cites this paper
• The protective effects of butorphanol tartrate against homocysteine-induced blood-brain barrier dysfunction

  2022cites this paper
• LY6E protein facilitates adeno-associated virus crossing in a biomimetic chip model of the human blood-brain barrier.

  2022cites this paper
• Redesigning therapies for pantothenate kinase–associated neurodegeneration

  2022cites this paper
• Small interfering RNAs based therapies for intracerebral hemorrhage: challenges and progress in drug delivery systems

  2022cites this paper
• Vesicle-Mediated Transcytosis and Export of Viruses

  2021cites this paper
• Apolipoprotein E, low-density lipoprotein receptor, and immune cells control blood-brain barrier penetration by AAV-PHP.eB in mice

  2021cites this paper
• Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models.

  2021cites this paper
• Investigating receptor-mediated antibody transcytosis using blood–brain barrier organoid arrays

  2021cites this paper
• Strategies for delivering therapeutics across the blood–brain barrier

  2021cites this paper
• BBB-crossing adeno-associated virus vector: An excellent gene delivery tool for CNS disease treatment.

  2021cites this paper
• Manufacturing challenges and rational formulation development for AAV viral vectors.

  2021cites this paper
• SEMMs: Somatically Engineered Mouse Models. A New Tool for In Vivo Disease Modeling for Basic and Translational Research

  2021cites this paper
• Functionality of a bicistronic construction containing HEXA and HEXB genes encoding β-hexosaminidase A for cell-mediated therapy of GM2 gangliosidoses

  2021cites this paper
• Formulation and delivery solutions for the next generation biotherapeutics.

  2021cites this paper
• PhP.B Enhanced Adeno-Associated Virus Mediated-Expression Following Systemic Delivery or Direct Brain Administration

  2021cites this paper
• SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration

  2021cites this paper
• Understanding the Potential of Genome Editing in Parkinson’s Disease

  2021cites this paper
• Capsid-Engineering for Central Nervous System-Directed Gene Therapy with Adeno-Associated Virus Vectors

  2021cites this paper
• Integrating in vitro disease models of the neurovascular unit into discovery and development of neurotherapeutics.

  2021cites this paper
• Multi-disciplinary Approach for Drug and Gene Delivery Systems to the Brain

  2021cites this paper
• Suicide Gene Therapy in Cancer and HIV-1 infection: an alternative to conventional treatments.

  2021cites this paper
• Battling Neurodegenerative Diseases with Adeno-Associated Virus-Based Approaches

  2020cites this paper
• Different Serotypes of Adeno-Associated Virus Vector- and Lentivirus-Mediated Tropism in Choroid Plexus by Intracerebroventricular Delivery

  2020cites this paper
• Brain HIV-1 latently-infected reservoirs targeted by the suicide gene strategy

  2020cites this paper
• Drug Delivery Strategies to Overcome the Blood-Brain Barrier (BBB).

  2020cites this paper
• Crossing the blood-brain barrier with AAV vectors

  2020cites this paper
• Synthetic immunomodulation with a CRISPR super-repressor in vivo

  2020cites this paper
• Investigating the Role of the 3’UTR of Claudin-5 and Circadian Rhythms at Tight Junctions in the Blood-Brain Barrier A thesis submitted to The University of Dublin for the degree of Master of Science 2020

  2020cites this paper
• Protein LY6E as a candidate for mediating transport of adeno-associated virus across the human blood-brain barrier

  2020cites this paper
• Efficient whole brain transduction by systemic infusion of minimally purified AAV-PHP.eB.

  2020cites this paper
• Viral Vectors for Neural Circuit Mapping and Recent Advances in Trans-synaptic Anterograde Tracers.

  2020cites this paper
• The blood-brain barrier studied in vitro across species

  2020cites this paper
• Engineered Extracellular Vesicles/Exosomes as a New Tool against Neurodegenerative Diseases

  2020cites this paper
• Positron emission tomography imaging of novel AAV capsids maps rapid brain accumulation

  2020cites this paper
• The GPI-Linked Protein LY6A Drives AAV-PHP.B Transport across the Blood-Brain Barrier.

  2019cites this paper
• Alzheimer Therapeutics

  2019cites this paper
• AAV-mediated gene therapy targeting TRPV4 mechanotransduction for inhibition of pulmonary vascular leakage

  2019cites this paper
• Clade F AAVHSCs cross the blood brain barrier and transduce the central nervous system in addition to peripheral tissues following intravenous administration in nonhuman primates

  2019cites this paper
• TOWARDS THE RATIONAL DESIGN AND APPLICATION OF POLYMERS FOR GENE THERAPY: INTERNALIZATION AND INTRACELLULAR FATE

  2019cites this paper
• Gene-targeting approaches for movement disorders: recent advances.

  2019influential citation
• Endothelial Cell Isolation and Manipulation

  2019cites this paper
• Fundamentals of Vascular Biology

  2019cites this paper
• Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery

  2019cites this paper
• Viral Vector Therapeutics Against Alzheimer’s Disease

  2019cites this paper
• Adeno‐associated virus‐based Alzheimer's disease mouse models and potential new therapeutic avenues

  2019influential citation
• Neurotropic Properties of AAV-PHP.B Are Shared among Diverse Inbred Strains of Mice.

  2019cites this paper
• AAV-Mediated Gene Delivery to the Spinal Cord by Intrathecal Injection.

  2019cites this paper
• Optimization of Dexamethasone Administration for Maintaining Global Transduction Efficacy of Adeno-Associated Virus Serotype 9

  2019influential citation